Skip to main content

Ultrack Systems Inc. (OTC: MJLB) Launches “PUR Rx” — A Scalable Digital Healthcare Platform Through Joint Venture with Synergy Health Rx Corp.

CONCORD, Ontario, June 26, 2025 (GLOBE NEWSWIRE) — Ultrack Systems Inc. (OTC: MJLB) is excited to announce the official launch of PUR Rx, a next-generation digital health platform formed through a 50/50 joint venture with Synergy Health Rx Corp. Designed to transform how Canadians access prescribed therapies, PUR Rx merges digital innovation with trusted medical infrastructure to deliver patient-first care at scale.

With the market for digital health in Canada expected to exceed CAD $4.7 billion by 2026 (Statista) and showing compound annual growth of 8.3%, PUR Rx arrives at a pivotal moment. The platform is poised to capture significant share in a sector driven by virtual care, streamlined prescriptions, and personalized healthcare delivery.

“PUR Rx is more than a joint venture—it’s a bold leap forward into the future of digital medicine,” said Reno Calabrigo, CEO of Ultrack Systems Inc. “This initiative perfectly blends our technology and branding strengths with Synergy Health’s healthcare credibility and regulatory footprint.”

Positioned at the Crossroads of Digital Health & Revenue Recurrence

PUR Rx leverages Ultrack’s proven capabilities in digital marketing, smart logistics, and user acquisition to accelerate platform growth and patient enrollment. Simultaneously, Synergy Health Rx contributes licensed infrastructure, prescription fulfillment, and a robust patient network, offering immediate operational scalability and regulatory compliance.

Key Platform Features:

  • Virtual care access & real-time eligibility checks
  • Prescription management through a licensed network
  • Secure portals for patients and providers
  • Data-driven marketing funnel to increase LTV (lifetime value) per user

Marketing-Driven Expansion with Ultrack at the Helm

Ultrack will lead the strategic rollout and brand development of PUR Rx through:

  • Paid digital campaigns targeting specific therapeutic verticals
  • SEO/SEM and geo-targeted outreach across Ontario
  • B2C and B2B lead funnels for patient and clinic acquisition
  • Investor-focused awareness campaigns and quarterly updates

Ultrack has committed to funding up to $10,000 per quarter in marketing spend through 2025, reflecting a lean but impactful customer acquisition strategy. This figure is expected to grow in 2026 as PUR Rx expands its footprint across Canada.

Competitive Advantage: Combining Agility with Compliance

While larger public digital health players like WELL Health Technologies and Dialogue Health Technologies have shown strong investor interest based on revenue growth and SaaS-style healthcare delivery models, PUR Rx differentiates itself through:

  • Joint ownership of infrastructure and patient data
  • Built-in fulfillment and regulatory compliance
  • Lower CAC (customer acquisition cost) due to Ultrack’s digital edge
  • Agility to pivot into emerging markets or underserved communities

These advantages offer institutional upside and retail investor appeal, especially as digital-first healthcare becomes the new norm post-pandemic.

Financial Outlook: Recurring Revenue, Scalable Model

The PUR Rx venture is targeting 25%–30% annual revenue growth over the next three years, supported by recurring service fees, prescription margins, and third-party payer partnerships. As the platform gains traction, expansion into additional Canadian provinces and telehealth integrations will enable new revenue streams and possible white-label licensing opportunities.

About Ultrack Systems Inc.

Ultrack Systems Inc. (OTC: MJLB) is a technology and logistics innovator focused on digital marketing, smart infrastructure, and operational scale across healthcare, transportation, and enterprise verticals. The company enables growth through turnkey branding systems, digital outreach, and strategic partnerships.

About Synergy Health Rx Corp.

Synergy Health Rx Corp. is a licensed health services provider specializing in prescription management, patient education, and coordinated care delivery across Ontario. Known for its advocacy-first approach, the company brings operational excellence and compliance assurance to PUR Rx.

INVESTOR NOTE:
With healthcare increasingly shifting toward virtual care, tech-enabled prescribing, and personalized patient experiences, MJLB’s launch of PUR Rx marks a high-leverage entry into a multi-billion-dollar, high-retention industry. Investors seeking exposure to the future of healthcare delivery—and the platforms that power it—should be watching Ultrack Systems Inc. closely.

Safe Harbor Statement
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release, including such forward-looking statements.

Investor Contact:
Email: info@ultrack.ca
Web: ultrack.ca, mybetterpets.com X: @UltrackI

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.